Blackline Inc.(BL)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BL Blackline Inc.

交易中 07-24 13:33:05 EDT

47.19

-0.55

-1.16%

最高48.46	最低47.15	成交量28.61万
今开47.93	昨收47.74	日振幅2.74%
总市值29.17亿	流通市值24.24亿	总股本6,182万
成交额1,361万	换手率0.56%	流通股本5,138万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"BL","market":"US","secType":"STK","nameCN":"Blackline Inc.","latestPrice":47.185,"timestamp":1721842384977,"preClose":47.74,"halted":0,"volume":286092,"delay":0,"floatShares":51377200,"shares":61817410,"eps":1.100874,"marketStatus":"交易中","marketStatusCode":2,"change":-0.555,"latestTime":"07-24 13:33:05 EDT","open":47.93,"high":48.46,"low":47.15,"amount":13614996.118716,"amplitude":0.02744,"askPrice":47.22,"askSize":297,"bidPrice":47.16,"bidSize":114,"shortable":3,"etf":0,"ttmEps":1.100874,"exchange":"NASDAQ","tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1721851200000},"adr":0,"listingDate":1477627200000,"adjPreClose":47.74,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":48.17,"preClose":47.74,"latestTime":"09:25 EDT","volume":300,"amount":14451,"timestamp":1721827500068},"postHourTrading":{"tag":"盘后","latestPrice":47.74,"preClose":47.74,"latestTime":"16:19 EDT","volume":72264,"amount":3449884.9338,"timestamp":1721765999563},"volumeRatio":0.44272,"impliedVol":0.6373,"impliedVolPercentile":0.9008},"requestUrl":"/m/hq/s/BL/tweets","defaultTab":"tweets","newsList":[{"id":"2450337763","title":"百利天恒(688506.SH)：注射用BL-M14D1(ADC)项目治疗晚期实体瘤获批I期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2450337763","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450337763?lang=zh_cn&edition=full","pubTime":"2024-07-11 18:45","pubTimestamp":1720694733,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百利天恒(688506.SH)发布公告，公司于近日收到国家药品监督管理局(NMPA)正式批准签发的《药物临床试验批准通知书》,公司自主研发的创新生物药BL-M14D1(ADC)的药物临床试验获得批准。BL-M14D1是与BL-B01D1出自同一小分子技术平台、与BL-B01D1共享同一“连接子+毒素”平台的ADC药物，其适应症为晚期实体瘤。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1149526.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1815336091.USD","BK4231","03347","LU0757428866.USD","BK4080","BK1141","BK1583","BK0239","ADC","BK4023","BK1576","688506","BL"],"gpt_icon":0},{"id":"2447166837","title":"内存制造技术再创新，大厂新招数呼之欲出","url":"https://stock-news.laohu8.com/highlight/detail?id=2447166837","media":"蓝鲸财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2447166837?lang=zh_cn&edition=full","pubTime":"2024-06-29 09:25","pubTimestamp":1719624309,"startTime":"0","endTime":"0","summary":"在高性能计算系统，特别是AI服务器中，内存的容量和带宽指标越来越重要，因为处理器需要处理巨量数据，传统DRAM已经无法满足需求。目前，HBM是当红炸子鸡。相对于传统DRAM，HBM的制造要复杂很多，它需要将多个DRAM裸片堆叠在一起，这就需要用到较为先进的封装技术了。HBM并不是高性能计算系统用内存的最终形态，从各大存储器厂商的研发方向来看，在存算一体彻底解决“存储墙”问题、相关芯片技术成熟并实现量产之前，3D DRAM将是HBM的继任者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/234303","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["DRAM","LU0757428866.USD","LU1815336091.USD","BK4023","BL"],"gpt_icon":0},{"id":"2446582501","title":"美国研究综述-Alphabet、Equity Residential、Infinera","url":"https://stock-news.laohu8.com/highlight/detail?id=2446582501","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446582501?lang=zh_cn&edition=full","pubTime":"2024-06-28 20:16","pubTimestamp":1719577011,"startTime":"0","endTime":"0","summary":"    路透6月28日 - 华尔街证券分析师周五调整了对几家美国上市公司的评级和目标价，其中包括 Alphabet、Equity Residential 和 Infinera。要闻 * Alphabet Inc   ：罗森布拉特证券公司将其评级从 \"买入 \"下调至 \"中性\"。* Cincinnati Financial Corp   ：花旗集团将其评级从 \"买入 \"上调至 \"买入 * Equity Residential   ：Piper Sandler将其评级从中性上调至增持 * 英飞朗  ：Stifel将其评级从 \"买入 \"下调至 \"持有 以下是路透周五报导的美国公司研究报告摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BHF","LU0106831901.USD","DAL","ACCD","T","AGCO","LU0061475181.USD","TXG","IE00BJTD4N35.SGD","BKR","AR","CALC","BB","LU0109391861.USD","LU2264538146.SGD","DCTH","CHPT","DAY","LU1280957306.USD","BWIN","CRK","CHK","CRL","DLR","DLTR","CHWY","APOG","ARRY","AVTR","LU0494093205.USD","CINF","LU0708995401.HKD","CERT","CMG","DE","AFL","ALSN","AOSL","BP","EQH","CRBG","AFG","AMP","ELAN","CTLT","BL","GOOGL","LU0128525929.USD"],"gpt_icon":0},{"id":"2446885253","title":"Blackline, Inc.盘中异动 下午盘股价大涨5.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2446885253","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446885253?lang=zh_cn&edition=full","pubTime":"2024-06-25 03:28","pubTimestamp":1719257295,"startTime":"0","endTime":"0","summary":"北京时间2024年06月25日03时28分，Blackline, Inc.股票出现波动，股价快速上涨5.37%。Blackline, Inc.股票所在的软件服务行业中，整体跌幅为0.53%。其相关个股中，Microalgo, Inc.、Banzai International Inc C/Wts 14/12/2028 、Arbe Robotics Ltd C/Wts 07/10/2026 涨幅较大，Microalgo, Inc.、Exela Technologies, Inc.、Freight Technologies, Inc.较为活跃，换手率分别为1622.05%、121.02%、25.09%，振幅较大的相关个股有Microalgo, Inc.、Digiasia Corp C/Wts 02/04/2029 、Banzai International Inc C/Wts 14/12/2028 ，振幅分别为235.75%、104.84%、57.52%。Blackline, Inc.公司简介：BlackLine Inc 致力于提供以软件即服务  形式交付的财务会计结算解决方案。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240625032815968164f6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240625032815968164f6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1815336091.USD","BK4023","LU0757428866.USD","BL"],"gpt_icon":0},{"id":"2445759585","title":"百利天恒(688506.SH)：注射用BL-M17D1(ADC)项目获批临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2445759585","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445759585?lang=zh_cn&edition=full","pubTime":"2024-06-21 20:09","pubTimestamp":1718971767,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百利天恒(688506.SH)发布公告，公司于近日收到国家药品监督管理局(NMPA)正式批准签发的《药物临床试验批准通知书》,公司自主研发的创新生物药BL-M17D1(ADC)的药物临床试验获得批准，同意本品单药在晚期实体瘤中开展临床研究。BL-M17D1是与BL-B16D1出自同一新的小分子技术平台、与BL-B16D1共享同一新的“连接子+毒素”平台的ADC药物，其适应症为晚期实体瘤。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1138904.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BL","BK4023","LU0757428866.USD","688506","LU1815336091.USD","BK1576","BK4080","BK1583","ADC","BK1141","BK4231","03347"],"gpt_icon":0},{"id":"2438285951","title":"百利天恒(688506.SH)：注射用BL-M07D1(HER2-ADC)III期临床试验完成首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2438285951","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2438285951?lang=zh_cn&edition=full","pubTime":"2024-05-26 15:45","pubTimestamp":1716709539,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百利天恒(688506.SH)发布公告，公司自主研发的创新生物药注射用BL-M07D1(HER2-ADC)单药用于局部晚期或转移性HER2阳性乳腺癌的III期临床试验已于近日完成首例受试者入组。BL-M07D1是靶向HER2的ADC药物，其适应症为乳腺癌、胃癌、非小细胞肺癌、妇科肿瘤、泌尿系统肿瘤等实体瘤。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1126166.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4080","BK4134","BK4023","BK1583","ADC","BK1141","LU1815336091.USD","BK0239","LU0757428866.USD","BK1576","BK4231","03347","III","BL","688506"],"gpt_icon":0},{"id":"2437494605","title":"百利天恒(688506.SH)：注射用BL-B01D1治疗HR+HER2-乳腺癌III期临床试验完成首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2437494605","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2437494605?lang=zh_cn&edition=full","pubTime":"2024-05-21 17:35","pubTimestamp":1716284130,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百利天恒(688506.SH)公告，公司自主研发的创新生物药注射用BL-B01D1(EGFR×HER3-ADC)单药用于局部晚期、复发或转移性HR+HER2-乳腺癌的III期临床试验已于近日完成首例受试者入组。据悉，BL-B01D1是公司自主研发的全球独家处于临床试验阶段的可同时靶向EGFR和HER3的双抗ADC药物。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1123910.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","LU0757428866.USD","BK0239","BK4225","BK1583","BK1576","03347","LU1815336091.USD","BK4023","BK4203","HR","BL","III","688506","BK4134"],"gpt_icon":0},{"id":"2435560853","title":"Blackline, Inc.2024财年第一财季实现净利润10.83百万美元，同比增加190.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2435560853","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2435560853?lang=zh_cn&edition=full","pubTime":"2024-05-13 00:18","pubTimestamp":1715530706,"startTime":"0","endTime":"0","summary":"3月31日，Blackline, Inc.公布财报，公告显示公司2024财年第一财季净利润为10.83百万美元，同比增加190.17%；其中营业收入为1.57亿美元，同比增加12.95%，每股基本收益为0.18美元。从资产负债表来看，Blackline, Inc.总负债17.75亿美元，其中短期债务2.54亿美元，资产负债比为1.18，流动比率为2.31。机构评级：截至2024年3月31日，当前有12家机构对Blackline, Inc.目标价做出预测，其中目标均价为63.03美元，其中最低目标价为49.00美元，最高目标价为81.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405130018308afe914f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405130018308afe914f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BL"],"gpt_icon":0},{"id":"2434916990","title":"百利天恒(688506.SH)：注射用BL-B16D1(双抗ADC)项目治疗晚期实体瘤获批I期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2434916990","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2434916990?lang=zh_cn&edition=full","pubTime":"2024-05-09 20:11","pubTimestamp":1715256671,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百利天恒(688506.SH)发布公告，公司自主研发的创新生物药BL-B16D1(双抗ADC)，于近日收到国家药品监督管理局(NMPA)正式批准签发的《药物临床试验批准通知书》。BL-B16D1是公司自主研发的偶联了新一代毒素的双抗ADC药物，其适应症为晚期实体瘤。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1119486.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1815336091.USD","BL","BK1141","BK1583","BK4023","BK1576","BK4231","BK0239","688506","ADC","LU0757428866.USD","BK4080","03347"],"gpt_icon":0},{"id":"2433747478","title":"Baird：维持BlackLine(BL.US)评级，由优于大市调整至优于大市评级, 目标价由61.00美元调整至72.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2433747478","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2433747478?lang=zh_cn&edition=full","pubTime":"2024-05-08 19:47","pubTimestamp":1715168859,"startTime":"0","endTime":"0","summary":"Baird：维持BlackLine(BL.US)评级，由优于大市调整至优于大市评级, 目标价由61.00美元调整至72.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405081947418ae8a0e7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405081947418ae8a0e7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BL"],"gpt_icon":0},{"id":"2429117922","title":"花旗：维持BlackLine(BL.US)评级，由中性调整至中性评级, 目标价由66.00美元调整至63.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2429117922","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2429117922?lang=zh_cn&edition=full","pubTime":"2024-04-24 00:25","pubTimestamp":1713889549,"startTime":"0","endTime":"0","summary":"花旗：维持BlackLine(BL.US)评级，由中性调整至中性评级, 目标价由66.00美元调整至63.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042400255187a6e0eb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042400255187a6e0eb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BL"],"gpt_icon":0},{"id":"2429309113","title":"Blackline, Inc.盘中异动 早盘快速拉升5.07%报61.35美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2429309113","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2429309113?lang=zh_cn&edition=full","pubTime":"2024-04-23 22:01","pubTimestamp":1713880892,"startTime":"0","endTime":"0","summary":"北京时间2024年04月23日22时01分，Blackline, Inc.股票出现波动，股价快速拉升5.07%。截至发稿，该股报61.35美元/股，成交量7.0134万股，换手率0.11%，振幅2.15%。Blackline, Inc.股票所在的软件服务行业中，整体涨幅为1.38%。Blackline, Inc.公司简介：BlackLine Inc 致力于提供以软件即服务  形式交付的财务会计结算解决方案。消息层面，截至22时01分，Blackline, Inc.股票正面舆情新闻比例100%。该信息摘要如下：Piper Sandler：上调BlackLine评级，由减持调整至中性评级, 目标价由55.00美元调整至62.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404232201327922b1dc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404232201327922b1dc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CYN","LU1815336091.USD","LU0757428866.USD","BK4023","BL"],"gpt_icon":0},{"id":"2429169672","title":"Piper Sandler：上调BlackLine(BL.US)评级，由减持调整至中性评级, 目标价由55.00美元调整至62.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2429169672","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2429169672?lang=zh_cn&edition=full","pubTime":"2024-04-23 17:35","pubTimestamp":1713864940,"startTime":"0","endTime":"0","summary":"Piper Sandler：上调BlackLine(BL.US)评级，由减持调整至中性评级, 目标价由55.00美元调整至62.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404231735458b4a03dc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404231735458b4a03dc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BL"],"gpt_icon":0},{"id":"2429151468","title":"美国研究综述-Blackline、Medpace Holdings、Roblox","url":"https://stock-news.laohu8.com/highlight/detail?id=2429151468","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2429151468?lang=zh_cn&edition=full","pubTime":"2024-04-23 15:25","pubTimestamp":1713857100,"startTime":"0","endTime":"0","summary":"    路透社4月23日 - 华尔街证券分析师周二调整了对几家美国上市公司的评级和目标价，其中包括 Blackline、Medpace Holdings 和 Roblox。公司要闻              * Blackline Inc   ：Piper Sandler将其评级从 \"减持 \"上调至 \"中性\"。* Medpace Holdings Inc   ：杰富瑞将其评级从 \"持有 \"上调至 \"买入\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXRX","CHD","BL","TRV","K","BK4533","NWBI","ARIS","IE00BD4GTW91.USD","TRGP","STBA","OCFC","TCBI","MODN","APOG","TFC","CACI","MP","BSRR","PCG","PAA","VZ","AMP","BK4534","ENLC","NEM","EPD","PAGP","BOH","BCBP","BRBR","CDE","BK4532","IE00BD4GTT62.SGD","ACI","RBLX","HBT","FOR","SFST","CCBG","IE00BLSP4239.USD","DTM","IE00BBT3K403.USD","BK4081","ELS","HL","MEDP","RGLD","LU0098860793.USD","IE00B1BXHZ80.USD"],"gpt_icon":0},{"id":"2429989921","title":"百利天恒(688506.SH)：“BL-B01D1+PD-1单抗±化疗”治疗局部晚期或转移性非小细胞肺癌获得II期临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2429989921","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2429989921?lang=zh_cn&edition=full","pubTime":"2024-04-21 16:27","pubTimestamp":1713688030,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百利天恒(688506.SH)发布公告，该公司自主研发的创新生物药注射用BL-B01D1(EGFR×HER3-ADC)相关的联合用药“BL-B01D1+PD-1单抗±化疗”，近日收到国家药品监督管理局(NMPA)正式批准签发的《药物临床试验批准通知书》。目前，BL-B01D1单药治疗末线鼻咽癌、二线食管鳞癌的临床研究已进入III期研究阶段。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1106093.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BL","LU1815336091.USD","03347","BK1583","LU1169589451.USD","BK1141","LU1169590202.USD","PD","BK1576","BK4023","LU0757428866.USD"],"gpt_icon":0},{"id":"2428239360","title":"百利天恒(688506.SH)：注射用BL-B01D1用于治疗局部晚期或转移性鼻咽癌末线患者纳入突破性治疗品种名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2428239360","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2428239360?lang=zh_cn&edition=full","pubTime":"2024-04-17 15:55","pubTimestamp":1713340500,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百利天恒(688506.SH)公告，公司自主研发的创新生物药注射用BL-B01D1(EGFR×HER3-ADC)用于治疗局部晚期或转移性鼻咽癌末线患者已被国家药品监督管理局药品审评中心(以下简称“药审中心”)纳入突破性治疗品种名单，近日已完成公示。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1103820.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BL","LU0757428866.USD","BK4023","LU1815336091.USD"],"gpt_icon":0},{"id":"2426414558","title":"Blackline, Inc.盘中异动 大幅下跌5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2426414558","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2426414558?lang=zh_cn&edition=full","pubTime":"2024-04-10 23:55","pubTimestamp":1712764541,"startTime":"0","endTime":"0","summary":"北京时间2024年04月10日23时55分，Blackline, Inc.股票出现波动，股价急速下挫5.00%。截至发稿，该股报65.18美元/股，成交量20.0856万股，换手率0.32%，振幅1.87%。Blackline, Inc.股票所在的软件服务行业中，整体跌幅为1.47%。Blackline, Inc.公司简介：BlackLine Inc 致力于提供以软件即服务  形式交付的财务会计结算解决方案。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041023554187e7f577&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041023554187e7f577&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1815336091.USD","BL","BK4023","LU0757428866.USD"],"gpt_icon":0},{"id":"2426140641","title":"Blackline, Inc.盘中异动 股价大涨5.02%报68.24美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2426140641","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2426140641?lang=zh_cn&edition=full","pubTime":"2024-04-10 03:31","pubTimestamp":1712691098,"startTime":"0","endTime":"0","summary":"北京时间2024年04月10日03时31分，Blackline, Inc.股票出现异动，股价大幅拉升5.02%。截至发稿，该股报68.24美元/股，成交量47.561万股，换手率0.77%，振幅4.77%。Blackline, Inc.股票所在的软件服务行业中，整体跌幅为0.06%。Blackline, Inc.公司简介：BlackLine Inc 致力于提供以软件即服务  形式交付的财务会计结算解决方案。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041003313887e7eeef&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041003313887e7eeef&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4023","LU0757428866.USD","LU1815336091.USD","AUUD","BL"],"gpt_icon":0},{"id":"2426168360","title":"百利天恒(688506.SH)：BL-B01D1III期临床试验已成功完成首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2426168360","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2426168360?lang=zh_cn&edition=full","pubTime":"2024-04-09 17:42","pubTimestamp":1712655726,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百利天恒(688506.SH)发布公告，公司自主研发的创新生物药注射用BL-B01D1(EGFR×HER3-ADC)正在开展用于复发性或转移性食管鳞癌的III期临床试验，已于近日成功完成首例受试者入组。据悉，BL-B01D1是公司自主研发的全球独家处于临床阶段的可同时靶向EGFR和HER3的双抗ADC药物，EGFR和/或HER3在大多数上皮肿瘤中呈高表达，BL-B01D1单药在多个上皮肿瘤适应症中均表现出强烈的疗效信号，特别是在非小细胞肺癌、小细胞肺癌、鼻咽癌、食管鳞癌、乳腺癌后线患者中，已表现出潜在的突破性疗效。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1100054.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4023","03347","BL","LU0757428866.USD","BK1583","BK1576","LU1815336091.USD","BK1141"],"gpt_icon":0},{"id":"2424444094","title":"百利天恒(688506.SH)：BL-M07D1相关的联合用药II期临床试验获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2424444094","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2424444094?lang=zh_cn&edition=full","pubTime":"2024-04-02 18:14","pubTimestamp":1712052874,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百利天恒(688506.SH)发布公告，公司自主研发的创新生物药BL-M07D1相关的联合用药“BL-M07D1+PD-1/PD-L1单抗±化疗”及“BL-M07D1+帕妥珠单抗±化疗”，近日收到国家药品监督管理局(NMPA)正式批准签发的《药物临床试验批准通知书》。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1097904.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU1815336091.USD","BL","BK1141","BK1583","BK1576","03347","LU0757428866.USD","BK4023"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.blackline.com","stockEarnings":[{"period":"1week","weight":-0.0193},{"period":"1month","weight":0.0414},{"period":"3month","weight":-0.2034},{"period":"6month","weight":-0.2057},{"period":"1year","weight":-0.1464},{"period":"ytd","weight":-0.2354}],"compareEarnings":[{"period":"1week","weight":-0.0196},{"period":"1month","weight":0.017},{"period":"3month","weight":0.0957},{"period":"6month","weight":0.1347},{"period":"1year","weight":0.2192},{"period":"ytd","weight":0.1651}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"BlackLine, Inc.以BlackLine Systems, Inc之名成立于2001年。该公司已经创建了一个全面的基于云计算的软件平台，旨在为所有类型和规模的组织变革和现代化的会计和财务运作。他们的安全可扩展的平台支持关键会计流程，如财务结算，对账，公司间的会计和控制的保证等。通过引入软件来自动化这些流程并使其能够持续运行，他们授权客户提高其财务报告的完整性，提高效率并增强其运营的实时可见性。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.026417},{"month":2,"riseRate":0.5,"avgChangeRate":0.024013},{"month":3,"riseRate":0.25,"avgChangeRate":-0.046622},{"month":4,"riseRate":0.625,"avgChangeRate":0.016571},{"month":5,"riseRate":0.625,"avgChangeRate":0.000833},{"month":6,"riseRate":0.875,"avgChangeRate":0.035947},{"month":7,"riseRate":0.5,"avgChangeRate":0.001952},{"month":8,"riseRate":0.571429,"avgChangeRate":0.031278},{"month":9,"riseRate":0.571429,"avgChangeRate":0.003938},{"month":10,"riseRate":0.428571,"avgChangeRate":-0.025077},{"month":11,"riseRate":0.75,"avgChangeRate":0.100615},{"month":12,"riseRate":0.375,"avgChangeRate":-0.008431}],"exchange":"NASDAQ","name":"Blackline Inc.","nameEN":"Blackline Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Blackline Inc.(BL)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Blackline Inc.(BL)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Blackline Inc.,BL,Blackline Inc.股票,Blackline Inc.股票老虎,Blackline Inc.股票老虎国际,Blackline Inc.行情,Blackline Inc.股票行情,Blackline Inc.股价,Blackline Inc.股市,Blackline Inc.股票价格,Blackline Inc.股票交易,Blackline Inc.股票购买,Blackline Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Blackline Inc.(BL)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Blackline Inc.(BL)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}